Displaying 1 - 2 of 2
| Active Ingredient | FILGRASTIM |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Prevention of neutropenia in patients receiving myelosup pressive cancer chemotherapy and to reduce the period of neutropenia in patients undergoing bone marrow transplantation |
| Caution | Musculoskeletal pain, dysuria |
| Dose Range |
Adjunct to antineoplastic therapy, filgrastim is given in a dose of 5 micrograms/kg daily starting not less than 24 hours after t he last dose of antineop lastic. Bone marrow transp lantation is 10 micrograms/kg daily , adjusted according to response. |
| Drug Interactions | |
| Pregnancy | Use only if potential benefit to mother justifies the risk to the fetus. |
| Breast Feeding | Use with caution for lactating women. |
| Active Ingredient | PEGFILGRASTIM |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |